Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Motor Neuron Disease Register for England, Wales, and Northern Ireland: Protocol for a Population Register.

JMIR research protocols·2026
Same author

Celebrating a breakthrough for amyotrophic lateral sclerosis.

Brain : a journal of neurology·2026
Same author

Erratum to "Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids" [Pharmacological Reviews 78 (2026) 100113].

Pharmacological reviews·2026
Same author

Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids.

Pharmacological reviews·2026
Same author

Mutant TDP-43 drives impairments in axonal transport and glycolysis in a mouse stem-cell-derived motor neuron model of amyotrophic lateral sclerosis (ALS).

Cell death & disease·2026
Same author

Targeted BDNF upregulation via upstream open reading frame disruption.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Related Experiment Video

Updated: Jun 27, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Biomarkers in amyotrophic lateral sclerosis.

Martin R Turner1, Matthew C Kiernan, P Nigel Leigh

  • 1Department of Clinical Neurology, University of Oxford, Oxford, UK. martin.turner@clneuro.ox.ac.uk

The Lancet. Neurology
|December 17, 2008
PubMed
Summary

Biomarkers are crucial for early amyotrophic lateral sclerosis (ALS) diagnosis and treatment. New research identifies potential biomarkers from fluid analysis and imaging to improve diagnosis and drug development for this progressive motor neuron disease.

More Related Videos

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Related Experiment Videos

Last Updated: Jun 27, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

Area of Science:

  • Neurology
  • Biomarker Research
  • Neurodegenerative Diseases

Background:

  • Amyotrophic lateral sclerosis (ALS), a progressive motor neuron disease, currently has limited treatment options, with riluzole being the only approved disease-modifying drug.
  • Diagnosis of ALS is primarily clinical, often delayed, potentially missing the optimal therapeutic window.
  • Current methods for assessing disease progression and therapeutic response, such as functional scales and survival rates, are insufficient.

Purpose of the Study:

  • To review the development of biomarkers for amyotrophic lateral sclerosis (ALS).
  • To explore how biomarkers can enhance diagnostic algorithms and identify new therapeutic targets.
  • To discuss the potential of biomarkers in improving clinical trial design and reducing reliance on animal models.

Main Methods:

  • Analysis of blood and cerebrospinal fluid.
  • Neuroimaging studies.
  • Neurophysiological assessments.

Main Results:

  • Identification of potential biomarkers sensitive to disease progression.
  • Biomarkers show promise for enhancing diagnostic accuracy and speed.
  • Biomarkers may enable earlier detection of therapeutic effects.

Conclusions:

  • Biomarkers are essential for advancing ALS diagnosis and treatment strategies.
  • Further research into biomarkers can lead to more effective drug development and personalized therapies.
  • Biomarkers may help overcome challenges in clinical trials, including phenotypic heterogeneity.